A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and is notorious for its resistance to both chemotherapy and small-molecule inhibitor targeted therapies. Subcellular targeted cancer therapy may thwart the resistance to produce a substantial effect. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Mrdenovic, Stefan, Wang, Yanping, Yin, Lijuan, Chu, Gina Chia-Yi, Ou, Yan, Lewis, Michael S., Heffer, Marija, Posadas, Edwin M., Zhau, Haiyen E., Chung, Leland W. K., Edderkaoui, Mouad, Pandol, Stephen J., Wang, Ruoxiang, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236852/
https://www.ncbi.nlm.nih.gov/pubmed/37268911
http://dx.doi.org/10.1186/s12885-023-10878-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236852/
https://www.ncbi.nlm.nih.gov/pubmed/37268911
http://dx.doi.org/10.1186/s12885-023-10878-3

Ejemplares similares